Greenville, South Carolina CCOP

位于南卡罗来纳州格林维尔的CCOP的长期目标包括：1）与格林维尔医院系统（GHS）重新建立统一的合作研究工作。2)巩固整个南卡罗来纳州北部的癌症预防和控制外展和通信吞吐量。3)增加参与与血液恶性肿瘤科学相关的辅助研究。4)通过我们新开发的外科肿瘤学专业知识提供的潜在创新手术技术，扩展我们的CCOP能力。5)进一步发展持续的CCOP治理，改进质量控制。6)参与NCI支持的干细胞移植研究。虽然我们存在的最初几年一直以受赠人和GHS之间的政治动荡为标志，但最近的事态发展使我们有理由相信，现在有可能采取统一的努力，这对这个社区和病人都有好处。我们将努力工作，确保保持这一势头。CCOP和该县两大医院之间的这种程度的效用和合作将肯定转化为改善癌症控制和预防工作。随着这一领域的发展，医疗专业知识和能力的多样性也在发展。以前超出我们研究范围的研究现在是可行的。随着我们的成熟，我们认为我们可以超越III期试验，为这一人群提供更多的东西。我们过去五年的成长之痛已经夺走了他们的工具。我们的主要优先工作是患者累积和及时，准确的数据提交。我们现在希望，由于我们已经达到了一定程度的成熟和稳定，我们将微调组织的治理，包括制定一个质量保证计划，其中包括我们必须努力实现的质量指标和参数。

The Greenville, South Carolina, CCOP has long-term objectives that include: 1) Re-establishing a unified and cooperative research effort with the Greenville Hospital System (GHS). 2) Solidification of cancer prevention and control outreach and communication throughput throughout the Upstate of South Carolina. 3) Increasing participation in ancillary studies associated with the science of hematologic malignancies. 4) Expansion of our CCOP capabilities associated with potentially innovative surgical techniques offered by our newly developed surgical oncology expertise. 5) Further development of a sustaining CCOP governance with improvement in quality control. 6) Participation in NCI-supported stem cell transplant research. While the initial years of our existence have been marked by political turmoil between the grantee and GHS, there are recent developments that give us cause to believe that a unified effort is now possible much to the gain of this community and it patients. We will work diligently to make certain that the momentum is maintained. This degree of utility and cooperation between the CCOP and the two major hospitals in this county will most certainly translate into an improved cancer control and prevention effort. As this area has grown, so too has the medical expertise and diversity of capabilities and diversity of capabilities. Studies that had before been beyond our research are now feasible. As we have matured, we feel that we can move beyond Phase III trials and offer this population something more. The growing pains of the last five years of our existence have taken their tool. Our major prioritized effort was that of patient accrual and timely, accurate data submission. We are now hopeful, as we have reached a degree of maturity and stability, that we will fine-tune the governance of the organization to include the development of a quality assurance program inclusive of quality indicators and parameters we must strive to achieve.